Royal Bank Of Canada decreased their price objective on shares of Novadaq Technologies to C$16.00 and set an "outperform" rating for the company in a research report on Wednesday, March 1st. The rating was downgraded by Craig Hallum on Monday, June 19 to "Hold". First Analysis has "Overweight" rating and $15 target.
U.S. Bancorp is a multi-state financial services holding company. The company presently has an average rating of "Buy" and an average price target of $11.84.
Rite Aid stock jumped 12% as speculators tried to guess what the Federal Trade Commission's final decision will be in the companys proposed merger with Walgreens Boots Alliance (NASDAQ: WBA). Pl Capital Advisors Llc owns 1.00 million shares or 4.85% of their United States portfolio. Novadaq Technologies Inc has $17 highest and $11 lowest target.More news: Puerto Rico Votes in Plebiscite on '500 Years of Colonial Status'
More news: President Trump's Lawyer: Not Aware of Any Investigation
More news: Special counsel probe turns to Jared Kushner's business dealings, report says
A West Michigan maker of medical devices and equipment is acquiring a Canadian medical imaging company for $701 million. The company has a 50 day moving average of $7.04 and a 200 day moving average of $7.19. (NASDAQ:NVDQ) has declined 24.90% since June 20, 2016 and is downtrending. (NASDAQ:NVDQ) to report earnings on July, 26. However, NOVADAQ securityholders will be permitted to make an election before the effective time of the Arrangement to receive their consideration in Canadian dollars by having the depositary arrange for such exchange on their behalf at the prevailing exchange rate. Equities research analysts anticipate that Novadaq Technologies will post ($0.80) earnings per share for the current year. "NOVADAQ's unique, innovative technology complements our advanced imaging portfolio and expands our product offerings into open and plastic reconstructive surgery". (NVDQ) Has Jumped To An 8-Month High After Merger" published on June 19, 2017 as well as Fool.com's news article titled: "Here's Why Novadaq Technologies Inc.
"We believe adding NVDQ's IP to Stryker will allow [it] to better grow the fluorescence field and we feel SYK is the most equipped company to do so", wrote Sean Lavin, an analyst with BTIG, in a research note Monday after the deal was announced.
"This acquisition aligns with Stryker's focus on enabling our customers to see and do more by enhancing cross-specialty surgical visualization", stated Timothy J. Scannell, Stryker's Group President, MedSurg and NeuroTechnology, in a news release. The stock inclined 65.49% last month and is up 21.62 this year. The medical research company reported ($0.24) EPS for the quarter, missing the Zacks' consensus estimate of ($0.21) by $0.03. Hedge funds and other institutional investors own 88.25% of the company's stock. After $-0.24 actual EPS reported by Novadaq Technologies Inc. for the previous quarter, Wall Street now forecasts -12.50% EPS growth. Its products are designed for use by surgeons in the operating room and other clinical settings where open, minimally invasive or interventional surgical procedures are performed.